Trials / Completed
CompletedNCT04869761
Stem Cell Therapy for Chronic Kidney Disease
Allogeneic Mesenchymal Stem Cell Therapy in Patients With Chronic Kidney Disease: A Phase I Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- LaTonya J. Hickson · Academic / Other
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.
Conditions
- Chronic Kidney Diseases
- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Type 1
- Diabetes Mellitus
- Diabetic Nephropathies
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion | Single MSC infusion of 150x10\^6 cells at time zero; intravenous delivery |
| DRUG | Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions | Two MSC infusions of 75x10\^6 cells at time zero and three months; intravenous delivery |
Timeline
- Start date
- 2021-10-07
- Primary completion
- 2023-04-26
- Completion
- 2023-04-26
- First posted
- 2021-05-03
- Last updated
- 2025-06-06
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04869761. Inclusion in this directory is not an endorsement.